Literature DB >> 7984969

Age specific prevalence of antibodies against Chlamydia pneumoniae in Iceland.

S Einarsson1, H K Sigurdsson, S D Magnusdottir, H Erlendsdottir, H Briem, S Gudmundsson.   

Abstract

Chlamydia pneumoniae is a newly recognized common cause of respiratory tract infections. The aim of this study was to examine its prevalence in Iceland. The study was based on 1020 serum samples from individuals 0-99 years old. The samples were divided into 10-year age groups. IgG and IgM antibodies were determined with microimmunofluorescence assay. An IgG titer > or = 32 and IgM titer > or = 16 were considered positive. The prevalence of positive IgG titer in the study population was 53 +/- 16% (mean +/- SD, age group range 14-66%). Neither seasonal nor gender-based difference in IgG antibody prevalence was demonstrated. It was lowest in the youngest group, 0-9 years old (p < 0.001), but rose linearly to age 70 (p < 0.005). 34 samples were IgM positive on initial testing; most from the older age groups. 12 were rheumatoid factor positive as well. After treatment with caprine antihuman IgG antibodies all became negative. The prevalence of C. pneumoniae infections is high in Iceland according to these results and similar to that in neighbouring countries. The presence of IgM rheumatoid factor may cause false positive tests for pathogen-specific IgM by immune complex binding with pathogen-specific IgG, thereby requiring its removal before testing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7984969     DOI: 10.3109/00365549409008610

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  A population based seroepidemiological survey of Chlamydia pneumoniae infections in schoolchildren.

Authors:  G Dal Molin; B Longo; T Not; A Poli; C Campello
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

Review 2.  Chlamydia pneumoniae and atherosclerosis.

Authors:  Y K Wong; P J Gallagher; M E Ward
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

3.  Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey.

Authors:  M Gencay; D Dereli; E Ertem; D Serter; M Puolakkainen; P Saikku; B Boydak; S Dereli; B Ozbakkaloglu; A Yorgancioglu; E Tez
Journal:  Eur J Epidemiol       Date:  1998-07       Impact factor: 8.082

4.  Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae.

Authors:  E M Peterson; L M de la Maza; L Brade; H Brade
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.